MedTrace Logo

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

NCT05333588 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-19

No results posted yet for this study

Summary

The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.

Conditions

  • Glioblastoma Multiforme, Adult

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

The autologous TILs will be intravenous infused into patients.

Sponsors & Collaborators

  • Hebei Senlang Biotechnology Inc., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunyan Li, academician · Member of the Chinese Academy of Engineering

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2024-02-15
Completion
2025-02-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05333588 on ClinicalTrials.gov